STOCK TITAN

Axonics to Report Fourth Quarter 2022 Financial Results on March 1

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Axonics, Inc. (NASDAQ: AXNX), a medical technology firm focused on bladder and bowel dysfunction, is set to release its fourth quarter 2022 financial results on March 1. A conference call will be held at 4:30 p.m. Eastern Time for discussion. Axonics has gained recognition, ranking No. 1 in the Financial Times Fastest Growing Companies in the Americas and No. 4 in Deloitte's Technology Fast 500 in 2022. Their sacral neuromodulation systems and Bulkamid® treatment are clinically effective options for managing overactive bladder and fecal incontinence, with established reimbursement across the U.S. and many European nations.

Positive
  • Ranked No. 1 on Financial Times 2022 Fastest Growing Companies in Americas.
  • Ranked No. 4 in Deloitte's 2022 Technology Fast 500.
  • Established reimbursement coverage in the U.S. and most European countries.
Negative
  • None.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1.

Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties may join the conference call by telephone by registering at the following link: Axonics 4Q22 registration. After registering, a confirmation email will be sent that includes the dial-in number and unique access code required to join the conference call by telephone.

For those not planning to ask a question on the conference call, the company recommends joining the live webcast, which can be accessed by visiting the following link: Axonics 4Q22 webcast. A replay of the webcast will be available shortly after the conclusion of the conference call and will be archived in the Events section of the Axonics investor relations website.

About Axonics®

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™ following its No. 1 ranking in 2021.

Axonics sacral neuromodulation (SNM) systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults affected by fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Axonics contact:

Neil Bhalodkar

949-336-5293

IR@axonics.com

Source: Axonics, Inc.

FAQ

When will Axonics report its fourth quarter 2022 financial results?

Axonics will report its fourth quarter 2022 financial results after the market closes on March 1, 2023.

What time is the Axonics conference call scheduled for?

The Axonics conference call is scheduled for 4:30 p.m. Eastern Time on March 1, 2023.

Where can I access the Axonics 4Q22 webcast?

The Axonics 4Q22 webcast can be accessed through their investor relations website.

What products does Axonics develop?

Axonics develops products for bladder and bowel dysfunction, including sacral neuromodulation systems and Bulkamid®.

How many adults are affected by overactive bladder and fecal incontinence?

An estimated 87 million adults in the U.S. and Europe suffer from overactive bladder, with an additional 40 million affected by fecal incontinence.

Axonics, Inc.

NASDAQ:AXNX

AXNX Rankings

AXNX Latest News

AXNX Stock Data

3.63B
50.43M
1.26%
87.22%
6.48%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
IRVINE